A 15-Year-Old’s Rare Skin Cancer Shows Promise with High-Dose Radiation
Physicians in a recent case report documented the regression of a rare skin cancer, primary cutaneous plasmacytoma, in a 15-year-old male after he received a high dose of electron beam radiotherapy, Cureus reported. The treatment, which delivered a total of 60 Gy in 30 fractions, successfully shrank the tumor without serious side effects, offering a potential new approach for this uncommon disease.
This case is significant because primary cutaneous plasmacytoma is an extremely rare form of cancer. Unlike its more common counterpart, multiple myeloma, which arises in the bone marrow, this cancer originates in the skin. The rarity of the condition means there is no standard treatment regimen, leaving clinicians to rely on a mix of surgical excision, radiation therapy, and chemotherapy, with varying degrees of success.
How a Rare Diagnosis Was Made
The patient, a 15-year-old boy, first noticed a small nodule on his left nasal wing. The lesion, which measured 9 mm, had a tendency to enlarge. After six months, he consulted a local physician and was referred to a hospital for a thorough evaluation. A biopsy was performed, and a pathologist examined the tissue under a microscope, revealing a dense infiltrate of abnormal plasma cells—fully differentiated B cells.
To confirm the diagnosis and rule out more widespread disease, a series of tests was conducted. Blood tests showed no abnormalities, and imaging scans of his body, including CT and MRI, found no other tumors. A bone marrow examination also came back clear. Tests for an abnormal protein called M protein, which is often a hallmark of plasma cell cancers, were negative. Based on these findings, the doctors confirmed a diagnosis of a solitary primary cutaneous plasmacytoma, meaning it was a single tumor that originated in the skin with no evidence of disease elsewhere in the body.
The Treatment Decision: Radiation at a Higher Dose
Given the location of the tumor on the young man’s face, surgical treatment was considered difficult; therefore, treatment using electron beams was performed. They planned to use a 6 MeV electron beam, a type of radiation that can be targeted to treat superficial skin tumors while sparing deeper tissues.
The initial treatment plan called for a dose of 50 Gy, delivered over 25 fractions. This dose is often recommended for extramedullary plasmacytomas—plasma cell tumors that occur outside the bone. However, after 46 Gy, the tumor had only begun to shrink, and the response was considered poor. The doctors faced a critical decision: stick with the planned dose or increase it to improve the chances of a cure.
Increasing the dose carried risks, including potential damage to the skin and underlying tissue. But the doctors were concerned that stopping at a lower dose could lead to a local recurrence. A recurrence would make future treatments, like re-irradiation or surgery, much more complicated and could necessitate systemic chemotherapy, which would be a significant burden for a teenager. After a thorough discussion with the patient and his family, the team made the decision to escalate the treatment, increasing the total dose to 60 Gy over 30 fractions. This decision was driven by the goal of achieving the best possible local control and minimizing the need for more aggressive therapy later on.
Tumor Shrinkage with High-Dose Radiation
- A 15-year-old boy with a rare skin cancer successfully treated it with a targeted, high-dose radiation therapy, leading to tumor shrinkage.
- For rare cancers without a standard treatment plan, doctors sometimes must make difficult choices, balancing the need for a cure against the risk of side effects.
- This case suggests that a higher-than-usual radiation dose may be an effective option for primary cutaneous plasmacytoma, especially when surgery isn’t feasible.
A Successful Outcome and Clinical Context
The higher dose proved to be effective. At the end of the 60 Gy treatment, the lesion had crusted over and shrunk from its original 9 mm to 7 mm. The only adverse event observed was mild dermatitis. Seven months after completing therapy, the lesion had flattened and further shrinkage was noted, showing no signs of recurrence. This outcome provides a valuable data point, as it adds to the limited body of evidence on treating this specific type of tumor with radiation alone.
A review of published cases reveals that reports of radiotherapy for primary cutaneous plasmacytoma are sporadic. According to a summary of nine cases treated with radiation alone, the total radiation dose has ranged from 20 Gy to 60 Gy. Among the cases with follow-up, most showed no recurrence, but one patient died five months after their disease recurred.
Regional Healthcare Access and Broader Implications
Consult a Doctor for Skin Lesions
Radiation therapy is not appropriate for all skin conditions or cancers.
A person should consult a doctor if they notice a new, persistent, or growing lump or lesion on their skin, especially if it is painful, bleeding, or changing in appearance. A dermatologist or oncologist can perform a biopsy to determine the nature of the lesion. Self-diagnosing or seeking unproven treatments based on a single case report is strongly discouraged. Management of any skin lesion should always begin with a professional medical evaluation to establish an accurate diagnosis and discuss all appropriate, evidence-based treatment options.
Funding and Data Integrity
This case report was published in Cureus, a peer-reviewed journal, and the authors did not report any specific funding source for the research or treatment described. The study is a single case report, which means it details the experience of one patient. While it provides valuable clinical insights, it does not represent the results of a large clinical trial with a control group.
| Key Data from Radiation Therapy Cases | Details |
|---|---|
| Treatment Modality | Electron Beam Irradiation |
| Total Dose | 60 Gy in 30 fractions |
| Patient Age | 15 years |
| Follow-up Duration | 7 months post-treatment |
| Reported Recurrence Rate in Similar Cases | One recurrence observed in nine cases treated with radiation alone |
Avoiding Invasive Treatments with Higher Radiation
By increasing the radiation dose from a standard 50 Gy to 60 Gy, the medical team was able to achieve gradual tumor shrinkage, effectively avoiding more invasive or systemic treatments.
References
- Tobikawa et al. “Tumor Regression Following Radiotherapy for Primary Cutaneous Plasmacytoma in a Young Patient: A Case Report.” Cureus.
- Li, Y., et al.
- Tsang, W.Y., et al.
- Him, R., et al.
- PubMed Central (PMC) Home Page Search PMC Full-Text Archive. U.S. National Institutes of Health’s National Library of Medicine (NIH/NLM).
